This company may still be operating, however this listing is no longer active. Find out why through their latest events.
BiVictriX Therapeutics Management
Management criteria checks 2/4
BiVictriX Therapeutics' CEO is Tiffany Thorn, appointed in Jan 2018, has a tenure of 6.67 years. total yearly compensation is £226.38K, comprised of 77.3% salary and 22.7% bonuses, including company stock and options. directly owns 1.98% of the company’s shares, worth €193.75K. The average tenure of the management team and the board of directors is 0.9 years and 3.1 years respectively.
Key information
Tiffany Thorn
Chief executive officer
UK£226.4k
Total compensation
CEO salary percentage
77.31%
CEO tenure
6.7yrs
CEO ownership
2.0%
Management average tenure
less than a year
Board average tenure
3.1yrs
Recent management updates
Recent updates
CEO Compensation Analysis
How has Tiffany Thorn's remuneration changed compared to BiVictriX Therapeutics's earnings?
Date
Total Compensation
Salary
Company Earnings
Jun 30 2024
n/a
n/a
-UK£3m
Mar 31 2024
n/a
n/a
-UK£3m
Dec 31 2023
UK£226k
UK£175k
-UK£3m
Sep 30 2023
n/a
n/a
-UK£2m
Jun 30 2023
n/a
n/a
-UK£2m
Mar 31 2023
n/a
n/a
-UK£2m
Dec 31 2022
UK£193k
UK£150k
-UK£2m
Sep 30 2022
n/a
n/a
-UK£3m
Jun 30 2022
n/a
n/a
-UK£3m
Mar 31 2022
n/a
n/a
-UK£3m
Dec 31 2021
UK£161k
UK£104k
-UK£2m
Compensation vs Market: Tiffany's total compensation ($USD296.22K) is below average for companies of similar size in the German market ($USD507.78K).
Compensation vs Earnings: Tiffany's compensation has increased whilst the company is unprofitable.
CEO
Tiffany Thorn (37 yo)
6.7yrs
Tenure
UK£226,375
Compensation
Ms. Tiffany Jane Thorn, M.Sc., serves as the Chief Executive Officer of BiVictriX Therapeutics Plc since 2018 and also serves as its Executive Director since June 22, 2021. She serves as the Chief Executiv...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Tiffany Thorn
CEO & Executive Director
6.7yrs
UK£226.38k
1.98% € 193.8k
Adrian Howd
Chief Business Officer & CFO
less than a year
no data
no data
Alison Lindsay
Secretary
less than a year
no data
no data
0.9yrs
Average Tenure
Experienced Management: 4DE's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Board Members
Name
Position
Tenure
Compensation
Ownership
Tiffany Thorn
CEO & Executive Director
3.3yrs
UK£226.38k
1.98% € 193.8k
Susan Lowther
Independent Non-Executive Director
3.1yrs
UK£39.00k
0.088% € 8.6k
Michael Kauffman
Non-Executive Chairman
2.7yrs
UK£35.00k
0.21% € 20.8k
Robert Hawkins
Independent Non-Executive Director
3.1yrs
UK£35.00k
0.39% € 38.6k
William Paris
Senior Independent Non-Executive Director
3.1yrs
UK£35.00k
0.18% € 18.0k
3.1yrs
Average Tenure
66.5yo
Average Age
Experienced Board: 4DE's board of directors are considered experienced (3.1 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2024/09/10 08:57
End of Day Share Price
2024/09/10 00:00
Earnings
2024/06/30
Annual Earnings
2023/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BiVictriX Therapeutics plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.